These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J; Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754 [TBL] [Abstract][Full Text] [Related]
13. Expectant management versus IUI in unexplained subfertility and a poor pregnancy prognosis (EXIUI study): a randomized controlled trial. Wessel JA; Mochtar MH; Besselink DE; Betjes H; de Bruin JP; Cantineau AEP; Groenewoud ER; Hooker AB; Lambalk CB; Kwee J; Kaaijk EM; Louwé LA; Maas JWM; Mol BWJ; van Rumste MME; Traas MAF; Goddijn M; van Wely M; Mol F Hum Reprod; 2022 Nov; 37(12):2808-2816. PubMed ID: 36331493 [TBL] [Abstract][Full Text] [Related]
14. Androgen and inhibin B levels during ovarian stimulation before and after 8 weeks of low-dose hCG priming in women with low ovarian reserve. Friis Wang N; Bogstad JW; Petersen MR; Pinborg A; Yding Andersen C; Løssl K Hum Reprod; 2023 Sep; 38(9):1807-1815. PubMed ID: 37354554 [TBL] [Abstract][Full Text] [Related]
15. Does dual oocyte retrieval with continuous FSH administration increase the number of mature oocytes in low responders? An open-label randomized controlled trial. Boudry L; Mateizel I; Wouters K; Papaleo E; Mackens S; De Vos M; Racca A; Adriaenssens T; Tournaye H; Blockeel C Hum Reprod; 2024 Mar; 39(3):538-547. PubMed ID: 38199789 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of ovarian stimulation agents for IUI in couples with unexplained subfertility. van Eekelen R; Wang R; Danhof NA; Mol F; Mochtar M; Mol BW; van Wely M Hum Reprod; 2021 Apr; 36(5):1288-1295. PubMed ID: 33615360 [TBL] [Abstract][Full Text] [Related]
17. BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle. Lobo R; Soerdal T; Ekerhovd E; Cohlen B; Porcu E; Schenk M; Shufaro Y; Smeenk J; Suerdieck MB; Pinton P; Pinborg A; Hum Reprod; 2024 May; ():. PubMed ID: 38723189 [TBL] [Abstract][Full Text] [Related]
18. Antral follicle count and anti-Müllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients. Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM Hum Reprod; 2021 May; 36(6):1530-1541. PubMed ID: 33822057 [TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes from ART in predicted hyperresponders: in vitro maturation of oocytes versus conventional ovarian stimulation for IVF/ICSI. Mostinckx L; Goyens E; Mackens S; Roelens C; Boudry L; Uvin V; Segers I; Schoemans C; Drakopoulos P; Blockeel C; De Vos M Hum Reprod; 2024 Mar; 39(3):586-594. PubMed ID: 38177084 [TBL] [Abstract][Full Text] [Related]
20. Serum progesterone is lower in ovarian stimulation with highly purified HMG compared to recombinant FSH owing to a different regulation of follicular steroidogenesis: a randomized controlled trial. Bosch E; Alamá P; Romero JL; Marí M; Labarta E; Pellicer A Hum Reprod; 2024 Feb; 39(2):393-402. PubMed ID: 38037188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]